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Abstract
The mTOR is a central regulator of cell growth and is
highly activated in cancer cells to allow rapid tumor growth.
The use of mTOR inhibitors as anticancer therapy has been
approved for some types of tumors, albeit with modest
results. We recently reported the synthesis of ICSN3250, a
halitulin analogue with enhanced cytotoxicity. We report
here that ICSN3250 is a speciﬁc mTOR inhibitor that oper-
ates through a mechanism distinct from those described for
previous mTOR inhibitors. ICSN3250 competed with and
displaced phosphatidic acid from the FRB domain in mTOR,
thus preventing mTOR activation and leading to cytotoxic-
ity. Docking and molecular dynamics simulations evi-
denced not only the high conformational plasticity of the
FRB domain, but also the speciﬁc interactions of both
ICSN3250 and phosphatidic acid with the FRB domain in
mTOR. Furthermore, ICSN3250 toxicity was shown to act
speciﬁcally in cancer cells, as noncancer cells showed up to
100-fold less sensitivity to ICSN3250, in contrast to other
mTOR inhibitors that did not show selectivity. Thus, our
results deﬁne ICSN3250 as a new class of mTOR inhibitors
that speciﬁcally targets cancer cells.
Signiﬁcance: ICSN3250 deﬁnes a new class of mTORC1
inhibitors that displaces phosphatidic acid at the FRB domain
of mTOR, inducing cell death speciﬁcally in cancer cells but
not in noncancer cells. Cancer Res; 78(18); 5384–97.2018 AACR.
Introduction
The serine/threonine kinase mTOR is a master regulator of cell
growth, highly conserved among eukaryotes (1, 2). mTOR is
organized in two structurally and functionally different com-
plexes: the rapamycin-sensitive mTORC1 (mTOR complex 1)
and the rapamycin-insensitive mTORC2 (mTOR complex 2;
refs. 3–6). mTORC1 is mostly activated by the presence of amino
acids, by growth factors, by the bioenergetics status of the cell, and
by oxygen availability. In the control of mTORC1 by growth
factors, the tuberous sclerosis complex (TSC) and the mTORC1
coactivator Rheb play a crucial role (7, 8). One of themechanisms
by which the TSC/Rheb pathway controls mTORC1 involves the
production of phosphatidic acid (PA), which binds directly to
mTOR at the FRB domain and activates mTORC1 downstream of
TSC/Rheb. Indeed, the downregulation of PA production is suf-
ﬁcient to decrease mTORC1 activity (9, 10).
As a major cell growth regulator, mTORC1 is recurrently
upregulated in cancer cells to allow rapid growth of tumors
(11). Indeed, the use of rapamycin analogues has been approved
as anticancer therapy for certain types of cancer. However, the
results of these treatments are very modest with respect to patient
survival and quality of life (12). Several reasons have been
invoked for these modest results in the clinics, including the
reactivation of a negative feedback loop downstream ofmTORC1
that activates the PI3K pathway (13), the absence of mTORC2
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inactivation upon rapamycin treatment (5), and recently, the
potential features of mTORC1 as a tumor suppressor (14, 15).
Still, inhibition of mTOR and the design of new compounds that
increase cancer cytotoxicity upon mTOR inhibition are active
ﬁelds of research, with recent reports proposing new-generation
mTOR inhibitors that overcome resistance tomTOR inhibition in
tumors and effectively induce tumor regression (16). However, to
date, most of these mTOR inhibitors tested either showed a
limited cytotoxicity toward cancer cells (havingmostly a cytostatic
effect) or showed an excessive cytotoxicity towardnoncancer cells,
thus increasing adverse side effects.
Recently, we reported the synthesis and cytotoxicity of
ICSN3250, an analogue of the cytotoxic marine alkaloid halitulin
(see Fig. 1A for the chemical structure of this compound; ref. 17).
Halitulin was ﬁrstly reported in 1998 as a bisquinolinylpyrrole
isolated from the sponge Haliclona tulearensis, showing cytotox-
icity against several tumor cell lines (18). Our previous work
concluded with the synthesis of a panel of halitulin analogues
through the formation of N-substituted 3,4-diarylpyrroles.
Among them, ICSN3250 (also called compound 25) was selected
as a very potent derivative, presenting a high cytotoxicity at a
nanomolar concentration in a caspase-independent cell death
mechanism (17). Our preliminary results indicated an increased
autophagy in cancer cells treated with ICSN3250. However, the
exact mechanism of action of ICSN3250 underlying its toxicity
and the speciﬁcity of this cytotoxicity toward highly proliferative
(cancer) cells were not examined previously.
In this report, we investigated the molecular mechanism by
which ICSN3250 induces toxicity in cancer cells. Starting from a
targeted screening analyzing several signaling pathways, we iden-
tiﬁed the mTORC1 pathway as a main target inhibited by
ICSN3250 in the nanomolar range. Our results indicated that
ICSN3250 inhibited mTORC1 by following an unprecedented
mechanism that involved its competition with PA at the FRB
domain of mTOR to overcome the TSC-negative regulation of
mTORC1. This particular mechanism of mTORC1 inhibition
Figure 1.
ICSN3250 speciﬁcally inhibited mTORC1 pathway. A, Chemical structure of ICSN3250. B, HCT116 cells were treated with the indicated concentration of ICSN3250
during 24 hours. Cell extracts were analyzed by Western blot to determine the activation of the indicated pathways. C–F, mTORC1 and autophagy activation in
HCT116 cells treated either with the indicated concentration of ICSN3250during 24 hours (C and E) orwith 100 nmol/L of ICSN3250 during the indicated time (D andF).
G and H, Autophagosome formation upon GFP-LC3 aggregation in GFP-LC3–expressing U2OS cells treated as indicated for 24 hours. Scale bar, 20 mm.
I, Cell-cycle distribution of HCT116 cells treated with the indicated concentration of ICSN3250 during 24 hours. J, SPR analysis of the interaction of ICSN3250
with mTOR, FRB domain, and streptavidin as negative control. Black arrow, injection of ICSN3250; white arrow, end of the injection.
Targeting Cancer Cells with a New Class of mTORC1 Inhibitor
www.aacrjournals.org Cancer Res; 78(18) September 15, 2018 5385
on January 10, 2019. © 2018 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst July 27, 2018; DOI: 10.1158/0008-5472.CAN-18-0232 
led to a potent and selective cytotoxicity observed in cancer cells
upon ICSN3250 treatment, which was not observed in noncan-
cer cells. Our results thus deﬁned ICSN3250 as a new class of
mTORC1 inhibitor and validated ICSN3250 as a potential anti-




3,4-diyl)bis(3-nitrobenzene-1,2-diol)) was synthesized as des-
cribed previously (17) and in a published patent application
WO2014/060366 (19). Brieﬂy, a new efﬁcient "one-pot" method
of unsymmetrically substituted pyrroles synthesis was applied. It
includes the condensationof ana-haloketone,ﬁrstwith aprimary
amine and then with an aldehyde. Subsequent intramolecular
cyclization of this in situ–generated b-ketoenamine (enamine
onto a ketone) results in formation of pyrrole-based ICSN3250
molecule.
Reagents and antibodies
Antibodies against mTOR (#2983, dilution 1:150), S6 (#2217,
dilution 1:1,000), phospho-S6 (Ser235/236; #4856, dilution
1:1,000), S6K (#2708, dilution 1:1,000), phospho-S6K(T389)
(#9205, dilution 1:1,000), 4EBP1 (#9452, dilution 1:1,000),
phospho-4EBP1(T37/46) (#2855, dilution 1:1,000), AKT
(#4691, dilution 1:1,000), phospho-AKT(Ser473) (#4060, dilu-
tion 1:1,000), phospho-AKT(Thr308) (#13038, dilution
1:1,000), AMPKa (#5832, dilution 1:1,000), phospho-AMPKa
(Thr172) (#2535, dilution 1:1,000), p53 (#2524, dilution
1:1,000), phospho-p53(Ser15) (#9284, dilution 1:1,000), p44/
42 MAPK (#4695, dilution 1:1,000), phospho-p44/42 MAPK
(Thr202/Tyr204) (#9106, dilution 1:1,000), p90RSK (#8408,
dilution 1:1,000), phosphor-p90RSK(Thr359/Ser363) (#9344,
dilution 1:1,000), phospho-p65(Ser536) (#3033, dilution
1:1,000), p62 (#5114, dilution 1:1,000), LC3 AB (#12741, dilu-
tion 1:1,000), b-actin (#4967, dilution 1:1,000), RAPTOR
(#2280, dilution 1:1,000), TSC2 (#4308, dilution 1:1,000), and
Flag (#14793, dilution 1:1,000) were obtained from Cell Signal-
ing Technology. Antibodies against p65 (#sc-8008, dilution
1:1,000) were obtained from Santa Cruz Biotechnology Inc.
Antibody against CD63 (SAB4700215, dilution 1:400) was
obtained from Sigma. The secondary antibodies anti-mouse
(#7076, dilution 1:1,000) and anti-rabbit (#7074, dilution
1:1,000) were obtained from Cell Signaling Technology. PA,
rapamycin, and paraformaldehyde were obtained from Sigma.
pcDNA3-FLAG-Rheb plasmid (Addgene #19996) was a gift from
Fuyuhiko Tamanoi (UCLA, Los Angeles, CA).
Cell lines and culture conditions
HCT116, U2OS, U87, and K562 cells were obtained from the
ATCC. GFP-LC3–expressing U2OS cells were kindly provided by
Eyal Gottlieb (Cancer Research UK). WT and TSC2–/– mouse
embryonic ﬁbroblasts (MEF) were kindly provided by David
J. Kwiatkowski (Harvard Medical School, Boston, MA). HCT116,
U2OS, and U87 cells were grown in DMEM high glucose (4.5 g/L;
GIBCO) and K562 cells in RPMI (GIBCO), both supplemented
with 10% of FBS (Dominique Dutscher), glutamine (2 mmol/L),
penicillin (Sigma, 100 U/mL), and streptomycin (Sigma, 100
mg/mL), at 37Cwith5%CO2 inhumidiﬁed atmosphere.Human
umbilical vein endothelial cells (HUVEC) were obtained from
Promocell (Germany) and cultured according to the supplier's
instructions in endothelial cell growthmedium2 containing growth
factors and 2% FCS. Primary normal human dermal ﬁbroblasts
(NHDF) derived from adult skin tissue were purchased from Lonza
and cultured according to the supplier's instructions in ﬁbroblast
growth medium containing human basic ﬁbroblast growth factor
(bFGF), insulin, and 2% FCS. Human follicle dermal papilla cells
(HFDPC) isolated from human dermis originating from lateral
scalp were purchased fromTebu-Bio and grown in Follicle Dermal
Papilla Cells Medium containing 4% FCS, 0.4% bovine pituitary
extract, 1 ng/mL bFGF, and 5 mg/mL of insulin (Tebu-Bio). The cells
were maintained at 37C in a humidiﬁed atmosphere containing
5% CO2. Mycoplasma contamination check was carried out using
the VenorGeM Kit (Minerva Biolabs GmbH). When indicated,
ICSN3250 (dissolved in DMSO before further dilution in assay
mixture)was added at the indicated concentration. PAwas added to
a ﬁnal concentration of 1, 10, or 100 mmol/L.
Isolation of patient-derived cancer cells and ﬁbroblasts
Resected colon tumor tissue was obtained from Bergonie
Institute (Bordeaux, France) following written-informed consent
approved by Bergonie Institute. Patient consent forms were
obtained at the time of tissue acquisition. Biopsies were deiden-
tiﬁed and processed for cell culture. Brieﬂy, to obtain a single cell
suspension, tumor tissue was cut into small fragments and enzy-
matically/mechanically dissociated with the gentle MACS Octo-
dissociator and the tumor dissociation kit for human (Miltenyi
Biotec). Single cells were then plated at 4.5  105 cell/mL in
96-well or 6-well plates previously coated with collagen I at 300
mg/mL (Rat tail, Gibco). ICSN 3250 (100 nmol/L) was immedi-
ately added to the cells. ICSN3250 did not affect the adhesion of
primary patient cells in culture (data not shown). Proliferation
was measured after 3 days of culture in 96-well plates by cell
counting and trypan blue exclusion with at least 3 replicates per
condition. Photomicrographs of control and treated cells were
taken at 3 days from 6-well plates (Nikon Eclipse TS100,
Archimed software from Microvision Instruments).
Coculture experiments
GFP-expressingHCT116orU2OS cancer cells were seededwith
GFP-negativeHUVECorNHDFcells in a ratio 1:1 and then treated
with ICSN3250 at different concentrations during 72 hours. Cells
were then collected and analyzed by ﬂow cytometry. The percent-
age of GFP-positive and -negative cells was calculated.
Plasmids and siRNAs transfections
Plasmid and siRNA transfections were carried out using
Jetpei and Interferin@ (Polyplus Transfection), respectively,
according to the manufacturer's instructions. Brieﬂy, 70% con-
ﬂuent cells were transfected with 5 mg of plasmid. Twenty-four
hours later, cells were treated with ICSN3250 for 24 more
hours. Cells at 50% of conﬂuence were transfected with siRNA
(ﬁnal concentration, 10 nmol/L) for 48 hours and then treated
with ICSN3250 for 24 hours. All siRNAs were obtained from
Dharmacon (on-target plus smartpool siRNA). Sequences of
nontargeting control siRNAs (D-001810-02-05) were (1)
UGGUUUACAUGUCGACUAA, (2) UGGUUUACAUGUUGU-
GUGA, (3) UGGUUUACAUGUUUUCUGA, and (4) UG-
GUUUACAUGUUUUCCUA, and sequences of TSC2 siRNAs
(L-003029-00-0005) were (1) GCAUUAAUCUCUUACCAUA,
(2) CGAACGAGGUGGUGUCCUA, (3) GGAAUGUGGCCU-
CAACAAU, and (4) GGAUUACCCUUCCAACGAA.
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Western blot
HCT116 cells, U2OS cells, NHDF,HUVEC, TSC2þ/þMEFs, and
TSC2/ MEFs were seeded in 10 cm plates. After the treatment,
cells were washed with PBS (1X) and lysed on ice using home-
madeRIPAbuffer (Tris-HCl 50mmol/LpH7.5,NaCl 150mmol/L,
NP-40 1%, sodiumdeoxycholate 0.5%, EDTA2mmol/L, andNaF
10 mmol/L) supplemented with protease inhibitors (Sigma),
phosphatase inhibitors (Sigma), and PMSF (1 mmol/L; Appli-
Chem). Protein quantiﬁcation was performed with the BCA assay
Kit (Thermo Fisher). After electrophoresis, the proteins were
transferred to a nitrocellulose membrane (BioRad) with Trans-
Blot Turbo Transfer System (Bio-Rad). The membranes were
incubated for 30 minutes in PBS 1X with 0.01% Tween-20 and
5%BSA. Primary antibodies were incubated overnight at 4C, and
secondary antibodies were incubated for 2 hours at room tem-
perature. Finally, membranes were imaged using the Chemi Doc
MP Imager (Bio-Rad).
In vitro kinase assays
In vitro kinase assays ofmTOR, AKT1, EGFR, PDK1, SRC, PKCa,
and PKCe were performed at CEREP Company (France). In vitro
kinase assays of PI3Ka, PI3Kb, PI3Kg , and PI3Kd were performed
using the PI3 Kinase Activity/Inhibitor ELISA assay from Merck-
Millipore. Detailed procedures of these in vitro kinase assays are
described in Supplementary Material and Methods.
Immunoprecipitation
After treatment, cells were washed twice with cold PBS, and
then they were lysed with lP lysis buffer (40 mmol/L Hepes,
pH 7.5, 120 mmol/L NaCl, 1 mmol/L EDTA, 0.3% CHAPS) and
supplemented with protease inhibitor cocktail and phosphatase
inhibitor cocktail (Sigma). Protein extracts were incubated over-
night at 4C with anti-mTOR antibodies and then for 4 hours at
4C with magnetic beads (Pierce Protein A/G Magnetic Beads,
ThermoFisher). Subsequently, beadswerewashed twicewith cold
PBS and eluted with Laemmli buffer for Western blot analysis.
Cell viability
To assess cell viability, 10,000 cells per well were seeded in
triplicate in 96-well plates. The number of cells was determined
using the TC20 Automated Cell Counter (Bio-Rad) according to
the manufacturer's protocol. Brieﬂy, after the respective treat-
ments, cells were detached with trypsin/EDTA, and 10 mL of the
cells suspension was mixed with 10 mL trypan blue 5% solution
(Bio-Rad) and analyzed with the cell counter. Alternatively, cell
viability was assessed using the CellTiter-Blue Cell Viability Assay
(Promega). After the treatment, 20 mL of the reagent was added to
each well, and the plate was incubated for 1 to 4 hours at 37C
with 5% CO2 in humidiﬁed atmosphere. The ﬂuorescence was
recorded at 560/590 nm in a Tristar2 LB942 (Berthold) device to
determine the cell viability.
Cell-cycle analysis
Exponentially growing cancer cells (HCT116 and U2OS) were
incubated with ICSN3250 or DMSO for 24 hours. Cell-cycle
proﬁles were determined by ﬂow cytometry using propidium
iodide on a FC500 ﬂow cytometer (Beckman–Coulter).
Surface plasmon resonance
Surface plasmon resonance (SPR) experiments were performed
at 25C (sample rack at 10C) on a Biacore T200 apparatus
(Biacore, GE Healthcare) using CM5 sensor chips (Biacore). The
surface was ﬁrst activated with a 7-minute pulse of 50 mmol/L
NHS/200mmol/L EDC (GEHealthcare) aqueousmixture using a
ﬂow rate of 5 mL/min. Streptavidin (IBA Lifesciences), full-length
(TP320457, Origene) and FRB-containing fragment (10012913,
Thermo Fisher) mTOR recombinant proteins were prepared in
10mmol/L sodiumacetate buffer (pH4.5 formTOR recombinant
proteins and pH 4.9 for streptavidin) and were injected in ﬂow
cells 2, 3, and 4, respectively. Note that 8,800 resonance units
(RU), 20,300 RU, and 12,300 RUwere immobilized, respectively.
The surface was then deactivated with a 7-minute pulse of
1 mol/L ethanolamine HCl-NaOH, pH 8.5 (GE Healthcare), and
washed with three 1-minute pulses of a mixture of 1mol/L NaCl/
50 mmol/L NaOH prepared in mq water. The ICSN3250 com-
pound (10 mmol/L) was prepared in the running buffer (PBS
containing 0.05% Tween-20) and was injected for 1 minute in
duplicate at 100 mL/min. The regeneration of the surface was
achieved with a 10-second pulse of SDS 0.05% at 30 mL/min
followed by an extra wash with running buffer. One channel left
blankwas used for referencing of the sensorgrams. The SPR signals
were normalized to the moles/mm2 of streptavidin immobilized
onto the sensor chip surface (ﬂow cell 2).
Confocal microscopy
Cells were grown on coverslips in 12-well plates. Subsequently,
after the treatments, cells were rinsed with ice-cold PBS and ﬁxed
with 4% paraformaldehyde in PBS for 30 minutes at room
temperature. After the ﬁxation, cells were permeabilized using
PBS with Triton-X 0.05% during 10 minutes and then blocked
with BSA 5% in PBS for 30 minutes. When required, cells were
incubated with primary antibody for 1 hour at 37C. After three
washes with PBS, the coverslip was incubated for 1 hour at 37C
with the appropriate secondary antibody (anti-rabbit Alexa488,
dilution 1:400 or anti-mouse Alexa555, dilution 1:400, obtained
from Invitrogen). Finally, coverslips were mounted with Prolong
containing DAPI (Invitrogen). Fluorescence was detected using a
Leica confocal microscopy. Images were analyzed using Image J
software.
Molecular modeling
Three-dimensional structures of ligands were generated using
CORINA version 3.44 (http://www.molecular-networks.com).
Molecular docking calculations were carried out using GOLD
software (20) and GoldScore scoring function, with the protein
2NPU (representative conformer 1; ref. 21) as receptor. The
binding site was deﬁned as a sphere with 15 Å radius around a
point with coordinates6.449, 6.669, and5.742. In agreement
with our previous studies (22–26) showing that an enhanced
conformational search is beneﬁcial, especially for largemolecules,
a search efﬁciency of 200% was used to better explore the ligand
conformational space. All other parameters were used with the
default values. Molecular dynamics simulations were carried out
with GROMACS version 4.6.5 (27) using the OPLS-AA (28) force
ﬁeld. Each systemwas energy-minimized until convergence using
a steepest descents algorithm. Molecular dynamics with position
restraints for 200 ps was then performed, followed by the pro-
duction run of 100 ns. During the position restraints and pro-
duction runs, the Berendsen method (29) was used for pressure
and temperature coupling. Electrostatics was calculated with the
particle mesh Ewald method (30). The P-LINCS algorithm (31)
was used to constrain bond lengths, and a time step of 2 fs was
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used throughout. Ligand topologies for the OPLS-AA force ﬁeld
were generated using MOL2FF, an in-house developed script, and
were deposited into the Ligandbook repository (32) with IDs
2929 (https://ligandbook.org/package/2929) and 2930 (https://
ligandbook.org/package/2930). DFT calculations were carried
out usingGaussian09, versionD01 (33). Experimental pKa values
were taken from Jencks and Regenstein (34). All calculations were
performed using the high-performance computing facilities avail-
able at the ICSN (Gif-sur-Yvette, France). Images were generated
with Pymol, version 1.8.6 (http://pymol.org).
Statistical analysis
The results are expressed as a mean  SEM of at least three
independent experiments. T test comparison was used to evaluate
the statistical difference between two groups. One-way ANOVA
followed by Bonferroni comparison as a post hoc test was used to
evaluate the statistical difference between more than two groups.
Statistical signiﬁcance was estimated when P < 0.05.
Data availability
The authors declare that all the data supporting the ﬁndings of
this study are available within the article and its Supplementary
Information ﬁles and from the corresponding author upon rea-
sonable request.
Results
ICSN3250 speciﬁcally inhibits mTORC1 pathway
To better understand the consequences at cell signaling level of
ICSN3250 (Fig. 1A) in human cells, we treated two human cancer
cell lines, the colorectal carcinoma cell line HCT116 and the
osteosarcoma cell line U2OS, with increasing concentrations of
ICSN3250, and we performed a targeted screening of different
signaling pathways. These included AMPK pathway (phospho-
Thr172 AMPK), p53 pathway (phospho-Ser15 p53), PI3K path-
way (phospho-Thr308 AKT), ERK pathway (phospho-Thr202/
Tyr204 p44/42 MAPK; phospho-Thr359/Ser363 RSK), NF-kB
pathway (phospho-Ser536 p65), mTORC1 pathway (phospho-
Thr389 S6K), and mTORC2 (phospho-Ser473 AKT). As shown
in Fig. 1B and Supplementary Fig. S1A, the only pathway that was
inhibited by ICSN3250 treatment in both cancer cells was
mTORC1 pathway. Indeed, some other pathways, such as PI3K,
ERK, andmTORC2, showed an increase in the phosphorylationof
their respective downstream targets. This increase would be in
agreement with a speciﬁc inhibition ofmTORC1pathway and the
subsequent release of the negative feedback loop that leads to
PI3K reactivation (13). To better evaluate the potential feedback
role that these activations would have upon ICSN3250 treatment,
we investigated the effect of ICSN3250 in both U2OS and
HCT116 cancer cells through long time-course experiments
(24, 48, and 72 hours). As shown in Supplementary Fig. S1B and
S1C, we observed that ICSN3250 treatment efﬁciently inhibited
mTORC1 activity even at that long term (72 hours). However,
the upregulation of PI3K, ERK, and NF-kB pathways observed at
short term was robustly attenuated at longer times. These
results indeed suggested that the upregulation of these path-
ways is a transient compensatory response of the cell, probably
due to the release of the negative feedback loop downstream of
mTORC1, having no major contribution to the long-term
effects of ICSN3250 in cancer cells.
Dose-dependent analysis showed a complete inhibition of
mTORC1 (looking at the phosphorylation of 3 well-known
targets of mTORC1 pathway: S6K, S6, and 4EBP1) at concentra-
tions equal or higher than 50 nmol/L of ICSN3250 (Fig. 1C;
Supplementary Fig. S1D). Time-course analysis showed a slow yet
efﬁcient inhibition of mTORC1 that reached a maximal inhibi-
tion upon 8 to 15 hours of treatment (Fig. 1D; Supplementary Fig.
S1E). This is considerably slower than previously reported
mTORC1 inhibitors, such as rapamycin or PP242. Conﬁrming
the capacity of ICSN3250 to inhibit mTORC1, we also observed
that ICSN3250 treatment induced an increase in autophagy,
negatively regulated by mTORC1 (35), as determined by increas-
ing levels of LC3-II, by decreasing levels of the adaptor
protein p62, and by the accumulation of GFP-LC3 puncta, all of
them standard markers of autophagy (Fig. 1E–H; Supplementary
Fig. S1F and S1G). Finally, ICSN3250 treatment caused cell-cycle
arrest at G0–G1 phase both in HCT116 cells and U2OS cells, as
expected upon mTORC1 inhibition (Fig. 1I; Supplementary
Fig. S1H).
To validate ICSN3250 as a direct inhibitor of mTORC1, we
investigated if ICSN3250 interacted directly with mTOR protein.
For this purpose, we performed SPR experiments using a recom-
binant mTOR peptide, including the full length of the protein. As
shown in Figure 1J, SPR analysis showed a direct interaction
between ICSN3250 and mTOR protein, whereas no interaction
with ICSN3250 was observed when a control protein (streptavi-
din) was used instead of mTOR, demonstrating the speciﬁc
interaction between mTOR and ICSN3250. In addition, we
repeated the analysis using only the FRB domain ofmTOR. Again,
SPR analysis showed a speciﬁc interaction of ICSN3250 with the
FRB domain of mTOR (Fig. 1J). Altogether, our results indicated
that ICSN3250 is an inhibitor of mTORC1 that directly interacts
with mTOR at the FRB domain.
ICSN3250 is not a kinase inhibitor of mTOR
Rapamycin and its analogues, as well as dual mTORC1/
mTORC2 inhibitors, act as kinase inhibitors of mTOR, with fast
time-course kinetics. We analyzed if ICSN3250 is a kinase inhib-
itor of mTOR in vitro. The results shown in Fig. 2A indicated that,
although ICSN3250 had a capacity to inhibit the mTOR kinase
activity, this effect occurred at concentrations much higher
(10 mmol/L) than the observed inhibition of mTORC1 in cells
(50 nmol/L) and is 105 times higher than the IC50 reported for
rapamycin (0.1 nmol/L; ref. 36). This result conﬁrmed that
ICSN3250 is not a kinase inhibitor of mTOR, suggesting that it
operates differently than other mTORC1 inhibitors. Indeed,
ICSN3250 did not show any inhibitory capacity neither toward
PI3Ka, b, g , or d (Supplementary Fig. S2A), nor toward other
kinases analyzed, such as PKCa, PKCe, SRC, AKT1, EGFR, and
PDK1 (Supplementary Fig. S2B).
ICSN3250 does not prevent lysosomal translocation of
mTORC1
Next, we investigated if ICSN3250 prevents the translocation of
mTORC1 to the surface of the lysosome, a well-known mecha-
nism involved in the activation of mTORC1 by nutritional inputs
(37). As shown in Fig. 2B, and quantiﬁed in Fig. 2C, the addition
of 100 nmol/L of ICSN3250 (a concentration at which mTORC1
was completely inhibited, see Fig. 1B and C) to HCT116 cells did
not prevent the colocalization of mTOR with the lysosomal
marker CD63, clearly indicating that lysosomal localization of
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mTORC1 was not impaired by ICSN3250. Similar results were
obtained in U2OS cells (Supplementary Fig. S2C and S2D).
Furthermore, even when ICSN3250 was not able to prevent the
amino acid–induced lysosomal translocation of mTORC1, still
ICSN3250 was able to prevent the activation of mTORC1 medi-
ated by amino acid in both cell lines (Fig. 2D; Supplementary Fig.
S2E), again suggesting that the inhibition of mTORC1 occurred
once mTORC1 is at the lysosomal surface. To ﬁnally discard that
lysosomal translocation is involved in themechanismof action of
ICSN3250, we overexpressed a delocalized Flag-Rheb, which
renders mTORC1 activation outside the lysosome. As expected,
Flag-Rheb overexpression induced mTORC1 activation in the
absence of amino acids (Supplementary Fig. S2F and S2G).
However, delocalized Flag-Rheb did not prevent the inhibitory
effect of ICSN3250 toward mTORC1 activity (Fig. 2E; Supple-
mentary Fig. S2H), ﬁnally conﬁrming that ICSN3250 operates
after the translocation of mTORC1 to the lysosome.
ICSN3250 does not destabilize mTORC1
mTORC1destabilization has been proposed as amechanismof
mTORC1 inhibition upon certain metabolic stresses (38). Thus,
we investigated if ICSN3250 destabilizes mTORC1 as an inhib-
itory mechanism. For this purpose, we immunoprecipitated
mTOR and analyzed the presence of the speciﬁc mTORC1 com-
ponent Raptor in the immunoprecipitates. As expected, in the
absence of the compound, Raptor was observed upon mTOR
immunoprecipitation (Fig. 2F). Our results showed that
ICSN3250 treatment (at 24 hours) was not able to prevent the
interaction of mTOR with Raptor (Fig. 2F). Hence, we concluded
that the mechanism of action of ICSN3250 does not affect the
integrity of the mTORC1, localized at the lysosome.
ICSN3250 antagonizes with PA to inhibit mTORC1
We next investigated the mechanisms that allow mTORC1
activation at the lysosome. These mechanisms are controlled by
the Tuberous Sclerosis Protein 1/2 complex (TSC complex) that
exerts a negative regulation towardmTORC1 (7). To investigate if
TSC complex plays a role in the mechanism of action of
ICSN3250, we treated TSC2þ/þ MEFs and TSC2/ MEFs with
increasing concentrations of ICSN3250. Similarly to what we
observed in cancer cell lines, ICSN3250 induced a complete
inhibition of mTORC1 at concentrations higher than 50 nmol/L
in TSC2þ/þ MEFs (Fig. 3A). Concomitantly, we observed an
activation of autophagy (as determined by increasing LC3II
levels), as expected upon mTORC1 inhibition. However, the
inactivationof TSC complex in TSC2/MEFs induced a complete
recovery of mTORC1 activity and a lack of autophagy activation
even in the presence of ICSN3250 at 100 nmol/L (Fig. 3A). These
Figure 2.
ICSN3250 did not act through mechanisms previously described for other mTOR inhibitors. A, In vitro kinase assay of mTOR in the presence of the indicated
concentrations of ICSN3250.B andC,mTOR localization inHCT116 cells treatedwith orwithout 100 nmol/L of ICSN3250during 24 hours, as indicated. CD63was used
as a lysosomal marker. D, mTORC1 activation in HCT116 cells treated with 100 nmol/L of ICSN3250 either in the presence or in the absence of amino
acids (AA) during 24 hours. E, mTORC1 activation in HCT116 cells transfected with either an empty vector or with a vector expressing Flag-Rheb and then
treated with or without 100 nmol/L of ICSN3250. F, Immunoprecipitation of mTOR in HCT116 cells treated with or without 100 nmol/L of ICSN3250.
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results were conﬁrmed by knocking down TSC2 in HCT116 and
U2OS cells. As shown in Fig. 3B and Supplementary Fig. S3A, the
efﬁcient silencing of TSC2 resulted in the reactivation ofmTORC1
in ICSN3250-treated cells. We concluded that the regulation of
mTORC1by TSC complexmight be involved in themechanismof
action of ICSN3250.
The production of PA by phospholipase D1 has been previ-
ously invoked as a mechanism of the regulation of mTORC1 by
TSC complex (39), and it is largely known that PA binds to and
activates mTORC1 (9). In addition, our previous results indicat-
ing that ICSN3250 interactswith the FRBdomainofmTOR,where
the pocket for PA is located, supported the hypothesis that
ICSN3250 could compete with PA in mTORC1 binding, thus
displacing PA from its binding site, leading to mTORC1 inhibi-
tion downstream of TSC complex. To test this possibility, we ﬁrst
performed a competitive analysis of mTORC1 activation between
PA and ICSN3250. For this purpose, we treatedHCT116 cells with
ICSN3250 (100 nmol/L) in the presence of increasing concentra-
tions of PA (0 to 100 mmol/L). As we observed previously,
ICSN3250 alone induced the inhibition of mTORC1. However,
coincubation of cells with PA induced a dose-dependent
mTORC1 reactivation and autophagy inhibition even in the
presence of ICSN3250 (Fig. 3C–F; Supplementary Fig. S3B and
S3C). Conversely, increasing concentrations of ICSN3250 limited
the activation of mTORC1 and the inhibition of autophagy
induced by PA (Fig. 3G and H; Supplementary Fig. S3D and
S3E). These results strongly suggest that ICSN3250 antagonizes
with PA to inhibit mTORC1.
ICSN3250 binds to the FRB domain of mTOR and displaces PA
To conﬁrm the previous conclusion that ICSN3250 antag-
onizes with PA, we performed molecular docking calculations
to identify the binding modes of ICSN3250 and PA within the
FRB domain of mTOR. Three different protonation states of the
catechol group in ICSN3250 were considered during the dock-
ing process (i.e., neutral and deprotonated on either OH
group), and the strongest interactions and the best protein-
ligand shape complementarity were obtained with the form
deprotonated on the OH-situated ortho from the NO2 substit-
uent. We computed the pKa of this OH group using the
protocol described by Muckerman and colleagues (DFT calcu-
lations on a simpliﬁed analogue of ICSN3250 with implicit
Figure 3.
ICSN3250 antagonized with phosphatidic acid to inhibit mTORC1. A, mTORC1 and autophagy activation in TSC2þ/þ and TSC2/ MEFs treated with increasing
concentrations of ICSN3250 for 24 hours. B, mTORC1 activation in HCT116 cells transfected either with a nontargeting siRNA or with an siRNA against TSC2
and then treated with ICSN3250 for 24 hours. C and D, mTORC1 and autophagy activation in HCT116 cells treated with increasing concentrations of PA in the
presence of 100 nmol/L ICSN3250. E and F, Autophagosome formation upon GFP-LC3 aggregation in GFP-LC3–expressing U2OS cells treated with 100 nmol/L
of ICSN3250 in the presence or absence of 100 mmol/L of PA. G and H, mTORC1 and autophagy activation in HCT116 cells treated with increasing concentrations
of ICSN3250 in the presence of 100 mmol/L PA.
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solvent and removal of the systematic error; ref. 40), and we
found a value of 5.93  0.55, meaning that this group is
negatively charged at physiologic pH. This is in strong agree-
ment with the docking results, showing interactions between
this group and the positively charged side chains of Lys2095 on
the one side and of Arg2042 on the other (Fig. 4A and B).
The FRB domain of mTOR (apo form) and the docking com-
plexes with ICSN3250 and PA were used for molecular dynamics
(MD) simulations (100 ns each), to take into account two factors
that were missing in the docking process: protein ﬂexibility and
the presence of explicit aqueous solvent. As expected, the apo
simulation reached very quickly an equilibrium conformation
that is conserved until the end. In contrast, the two complexes
evolved slowly toward an equilibrium structure, which is attained
only after 75 to 80 ns (Supplementary Fig. S4A–S4C), highlight-
ing the need for relatively long MD simulations in the study of
Figure 4.
FRB domain of mTOR adopts different conformations in the apo form and in complex with ICSN3250 and PA. A and B, Representative conformation for FRB
domain ofmTOR (apo form) extracted from a 100 nsMD simulation.C–F,Representative conformations for complexes between FRBdomain ofmTORand ICSN3250
(C and D) or PA (E and F) extracted from 100 ns MD simulations. The protein and the ligands (ICSN3250 and PA) are shown as surface representations
colored in gray, magenta, and orange, respectively.
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ﬂexible proteins. The representative equilibrium structures from
these simulations showed a number of interesting elements. The
protein surface is veryﬂexible, changing the shape according to the
interaction partner. Consequently, a very good protein-ligand
surface complementarity was observed for the two complexes,
bringing an important contribution to the ligand afﬁnity, which is
complementedby strong ionic interactions betweennitrocatechol
groups and Lys2095 and Arg2042 in the case of ICSN3250
and between the phosphate group and Arg2109 in the case
of PA (Fig. 4C and F). The interaction between ICSN3250 and
its binding site showed three distinct regions: (i) the ionic inter-
action between the nitrocatechol groups and Lys2095 and
Arg2042 that was already mentioned; (ii) a p-stacking interaction
between the pyrrole ring and Phe2039, and (iii) the interaction
between themacrocycle and a hydrophobic subpocket composed
of residues Trp2101, Tyr2105, Phe2108, Leu2031, and Tyr2104.
Ser2035, which was shown to be important for the interaction
of mTOR with rapamycin (41), is also part of the binding site
(Fig. 5A and B). ICSN3250 is relatively ﬂat on the protein surface,
whereas PA is deeply buried with its two hydrophobic tails that
interact with a subpocket containing Trp2101, Tyr2105, Phe2108,
Leu2031, Leu2054, Tyr2104, Ser2035, Phe2039, Leu2051,
Tyr2038, Val2044, and Met2047. Only the phosphate head is
solvent-exposed and interacts with Arg2109 (Fig. 5C and D). This
orientation is similar to the one previously observed by NMR
(21), with the exception of the tail chains that are more deeply
buried in our case.
Overall, the residues involved in the interaction between
mTOR and the two ligands studied in this work clearly show a
signiﬁcant overlapping of the two binding sites. Our results
supported that ICSN3250 binds to the FRB domain of mTOR
and displaces PA, leading to mTORC1 inhibition. This mech-
anism deﬁnes ICSN3250 as a new class of mTORC1 inhibitor.
Inhibition of mTORC1 by ICSN3250 is responsible for its
cytotoxicity in cancer cells
Previously, we reported that ICSN3250 showed an increased
cytotoxicity in human cells (17). We have now conﬁrmed that
no radical intermediate can be observed by electron spin
resonance in vitro with ICSN3250 in the presence of superoxide
anion, the main ROS in cells (Supplementary Fig. S5A). We also
observed that ICSN3250 did not react with superoxide
Figure 5.
ICSN3250 and PA have partially overlapping binding sites. A–D, Residues involved in the interactions with ICSN3250 (A and B) and PA (C and D). The protein
is colored in gray and represented in cartoon mode. Protein residues involved in interactions, and the ligands ICSN3250 and PA are represented in stick
mode and colored in green, magenta, and orange, respectively. Ionic interactions and hydrogen bonds are represented as dashed lines.
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(Supplementary Fig. S5B), conﬁrming the redox stability of
ICSN3250. In addition, as shown in Supplementary Fig. S5C
and S5D, ICSN3250 did not induce an increase of ROS levels,
neither at the cytosol nor at the mitochondria. In agreement
with these results, we also observed that the cytotoxicity of
ICSN3250 in HCT116 was not reversed (neither partially
reduced) by treating the cells with N-acetylcysteine, a classical
antioxidant (Supplementary Fig. S5E). These results indicated
that the cytotoxicity exerted by ICSN3250 in cancer cells is not
mediated by a potential increase in ROS levels.
Our results demonstrating that ICSN3250 acts as a new class
of mTOR inhibitor led us to investigate if the inhibition of
mTORC1 was the primary reason for the cytotoxicity induced by
ICSN3250. For this purpose, we investigated if the reactivation of
mTORC1 mediated by TSC ablation in TSC2/ MEFs protected
from the cytotoxic effect of ICSN3250. As shown in Fig. 6A and
Supplementary Fig. S6A, TSC2/ MEFs showed an increased
protection against cytotoxicity induced by ICSN3250with respect
to TSC2þ/þ MEFs (as control, TSC2/ MEFs did not show any
increased viability with respect to TSC2þ/þ in the absence of
ICSN3250). Similar results were obtained when TSC2 was
knocked down in HCT116 or U2OS cells: the efﬁcient silencing
of TSC2 was sufﬁcient to restore (at least partially) cell viability in
ICSN3250-treated cells (Fig. 6B; Supplementary Fig. S6B).
We previously showed that treatment of HCT116 cells with PA
(100 mmol/L) was sufﬁcient to reactivate mTORC1 (see Fig. 3B).
Now,we conﬁrmed that PA treatment alsoprevented the cytotoxic
effect of ICSN3250 in a dose-dependent manner in HCT116 cells
(Fig. 6C–E). This result clearly suggested that the inhibition of
mTORC1 by ICSN3250 is responsible for its cytotoxicity. Fur-
thermore, the particular mechanism of mTORC1 inhibition
induced by ICSN3250 is likely the reason of the increased cyto-
toxicity showed by this compoundwith respect to othermTORC1
inhibitors, such as rapamycin. Indeed, although rapamycin
induced a stronger inhibition of mTORC1 than ICSN3250 (Fig.
6F), it did not cause the cytotoxic effect that we observed upon
ICSN3250 treatment (Fig. 6G). Compared with a panel of mTOR
inhibitors, ICSN3250was not themost potentmTORC1 inhibitor
among them as determined by the dephosphorylation of
mTORC1-downstream targets (Supplementary Fig. S6C and
S6D), but yet it ranked among the most cytotoxic compounds
for cancer cells, showing one of the lowest IC50 values (Fig. 6H;
Supplementary Fig. S6E). Hence, we concluded that the qualita-
tive (and not quantitative) differences between the inhibition
Figure 6.
Inhibition of mTORC1 by ICSN3250 is responsible for its cytotoxicity in cancer cells. A, Cell viability of TSC2þ/þ and TSC2/ MEFs treated with or without
ICSN3250 100nmol/L for 72hours.B,Cell viability ofHCT116 cells transfected eitherwith a nontargeting siRNAorwith an siRNAagainst TSC2 and then treatedwith or
without ICSN3250 100 nmol/L for 24 hours. C, Cell viability of HCT116 cells treated with increasing concentrations of PA in the presence of 100 nmol/L ICSN3250.
D and E, Cell viability (D) and representative microscopy images (E) of HCT116 cells treated with increasing concentrations of ICSN3250 in the presence of
100 mmol/L PA. F and G, mTORC1 activation (F) and cell viability (G) of HCT116 cells treated either with 100 nmol/L rapamycin or with 100 nmol/L ICSN3250.
H, IC50 values of different mTOR inhibitors in HCT116 cells.
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exerted by ICSN3250 with respect to other mTOR inhibitors are
key for the marked cytotoxicity induced by ICSN3250.
ICSN3250 speciﬁcally targets cancer cells both in vitro and
ex vivo
To validate the potential applicability of ICSN3250 as an
anticancer drug, we compared the cytotoxicity of ICSN3250 in
a panel of cells including both cancer cells and noncancer cells. As
shown in Fig. 7A, ICSN3250 showed a cytotoxicity in cancer cells
(HCT116, U2OS, U87, and K562) that was 10 to 100 times more
potent than its cytotoxicity in human noncancer cells (NHDF,
HUVEC, and HFDPC; MEFs, as they are highly proliferating, do
not really behave as normal cell in culture, and theywere sensitive
to ICSN3250). Lack of toxicity in noncancer cells (NHDF and
HUVEC) was conﬁrmed in long time-course experiments, at 72
hours of treatment, in clear contrast with cancer cells (HCT116
and U2OS; Fig. 7B and C; Supplementary Fig. S7A and S7B).
Importantly, the reduced cytotoxicity of ICSN3250 observed in
noncancer cells correlated with its reduced capacity to inhibit
mTORC1 in these cells: the inhibition ofmTORC1 inHUVEC and
NHDF cells was only reached at concentrations higher than
500 nmol/L (Fig. 7D; Supplementary Fig. S7C), whereas full
mTORC1 inactivation in U2OS and HCT116 cells was observed
at 50 nmol/L (see Fig. 1C; Supplementary Fig. S1D).
To further sustain the notion that ICSN3250 exhibits selec-
tivity for cancer cells over noncancer cells, we performed
coculture experiments of GFP-labeled cancer cells (HCT116 or
U2OS) together with unlabeled noncancer cells (HUVEC and
NHDF) treated with increasing concentrations of ICSN3250 for
72 hours. Flow cytometry analysis showed a clear decrease in
the GFP-positive (cancer cells) population with respect to the
GFP-negative (noncancer cells) population (Fig. 7E–G; Sup-
plementary Fig. S7D–S7F). These results corroborated that
ICSN3250 exhibits selective cytotoxicity toward cancer cells.
Next, in order to validate the capacity of ICSN3250 to target
primary cancer cells, we performed ex vivo treatment of cancer
cells from a patient with colorectal cancer. As shown in Fig. 7H–
J, we observed a substantial decrease in the viability of these
primary cancer cells after 72 hours of treatment with ICSN3250
ex vivo. Importantly, primary ﬁbroblasts obtained from the
Figure 7.
ICSN3250 speciﬁcally targets cancer cells both in vitro and ex vivo. A, Cell viability of both cancer (squares) and noncancer (circles) cell lines treated with different
concentrations of ICSN3250 as indicated. B and C, Cell proliferation curves of NHDF (B) and HCT116 (C) cells treated with increasing concentrations of ICSN3250. D,
mTORC1 activation in NHDF cells treated with increasing concentrations of ICSN3250 for 24 hours. E–G, Flow cytometry analysis of GFP-positive HCT116 cells and
GFP-negative NHDF or HUVEC cells cocultured for 72 hours in the presence of increasing concentrations of ICSN3250. H–J, Primary cancer cells and primary
ﬁbroblast from a patient with colorectal cancer were isolated and treated with ICSN3250 100 nmol/L for 72 hours. Cell viability was determined by microscopy (H),
and cell number was quantiﬁed (I and J). K, IC50 values of different mTOR inhibitors in the noncancer cells NHDF. ns, nonsigniﬁcant.
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same patient failed to show any decrease in viability upon
ICSN3250 treatment. These results conﬁrmed the validation
and speciﬁcity of ICSN3250 to kill primary cancer cells.
Finally, compared with other mTOR inhibitors that showed
cytotoxicity in cancer cells (such as INK 128, gedatolisib, or VS-
5584, among others), ICSN3250 was substantially less toxic in
human primary normal cells (Fig. 7K), supporting the concept
that ICSN3250 presents an action mechanism that makes it
particularly interesting to develop anticancer strategies.
Discussion
The results shown herein presented ICSN3250 as a new class of
mTORC1 inhibitor that acts through a mechanism that differs
from those described by other mTOR inhibitors. ICSN3250 is an
analogue of the cytotoxic marine alkaloid halitulin, previously
reported to present an increased cytotoxicity (17). However, the
mechanism of action underlying this cytotoxicity was not known.
Our results showed a speciﬁcity of ICSN3250 targeting mTORC1,
without inhibiting other signaling pathways, such as AMPK, p53,
PI3K, ERK, NF-kB, or evenmTORC2. Surprisingly, ICSN3250 did
not affect the kinase activity of mTOR, neither the stability of
mTOR complex. Instead, our results showed that ICSN3250binds
to the FRB domain of mTOR, displacing PA to overcome the TSC-
negative regulation of mTORC1 as a mechanism for mTORC1
inhibition. Indeed, increasing amounts of exogenously added PA
or TSC ablation restoredmTORC1 activity. This competition with
PA seems to be key for the cytotoxicity of ICSN3250, as exoge-
nously addedPAnot only restoredmTORC1, but also restored cell
viability. Of note, ICSN3250 did not show an increased capacity
to inhibit mTORC1 with respect to previously reported mTOR
inhibitors, but yet it showed a particularly high cytotoxic effect in
cancer cells, showing a lower IC50 than typical inhibitors such as
temsirolimus, accepted by FDA as a treatment against renal cell
carcinoma. Importantly, the cytotoxicity of ICSN3250 toward
noncancer cells is substantially lower than the most potent of
the other inhibitors of mTOR, placing ICSN3250 as a good
candidate for future clinical assays.
mTOR inhibition has been approved as a cancer therapy for
several types of tumor (42). Yet, the efﬁciency of those treatments
is very modest. Rapamycin and analogues showed mostly cyto-
static effect, which in the patient results in a mild delay of tumor
growth, with little effect (although statistically signiﬁcant) in
patient survival. These modest results have been explained by
the reactivation of the PI3K pathway as a consequence of the
release of negative feedback loop downstream of mTORC1 (13).
This is why a new generation of dual mTORC1/mTORC2 inhi-
bitors and PI3K/mTOR inhibitors are being proposed and tested.
However, these inhibitors still show increased cytotoxicity in
noncancer cells. Besides, theuse ofmonotherapies targeting single
signaling pathways to treat cancer is under reconsideration. Due
to the intrinsic genetic heterogeneity of tumors and the rapid
evolution and adaptation of tumor cells during the progression of
the disease (43), developing drug resistance is a recurrent problem
during treatment, particularly when monotherapies have been
used. Still, the efﬁcacy of ICSN3250 to selectively target tumor
cells in vivo remains to be elucidated.
As mTORC1 is not the only protein activated by PA, it could be
envisioned that othermechanisms or pathways could be involved
in ICSN3250-induced cytotoxicity. However, our results showing
that mTORC1 reactivation in TSC2/ cells restored cell viability
indicated that mTORC1 inhibition is at the basis of ICSN3250-
induced cytotoxicity. The unprecedented mechanism of action of
ICSN3250, displacing PA to overcome TSC-negative regulation of
mTORC1,without affectingmTORkinase activity, seems to be key
to explain the speciﬁc cytotoxicity for cancer cells showed by this
type of mTORC1 inhibitor. Why this mechanism of action would
bemore cytotoxic thanmTORkinase inhibitionmediated byATP-
competitive inhibitors would require further investigations. As
ICSN3250-induced PA displacement from the FRB domain of
mTOR would likely occur at the surface of the lysosome (where
mTORC1 is located upon activation), it could be hypothesized
that this displacement causes a collapse in the lysosomal surface,
perturbing lysosomal function and leading to cell death, as
proposed for other types of stress (44). Alternatively, the slower
inactivation of mTORC1 mediated by ICSN3250 as compared
with other mTOR inhibitors that we observed could be playing in
favor of its cytotoxicity, as our recent results showed that a fast and
complete inhibition of mTORC1 upon rapamycin treatment
prevents apoptotic cell death during nutritional imbalance (14).
Finally, our results make particular emphasis in the control of
mTORC1 activity by PA, a regulation that has not received as
much attention as the regulation exerted by amino acids or by
PI3K signaling. However, our results clearly indicated that inter-
fering with PA binding in the FRB domain of mTOR is indeed an
effective approach to inhibit mTORC1 even in the presence of
amino acids and growth factors, underscoring the importance of
PA for mTORC1 activity. Besides, as mentioned above, the reg-
ulation of mTORC1 by PA seems to be particularly important at
the cell physiology level, as the interference with the mTOR–PA
interaction resulted in cell death. How exogenously added PA
results in mTORC1 activation is not clear (9, 45, 46). In our
experiments, we needed a substantially higher concentration of
PA to compete with ICSN3250, probably reﬂecting that the
concentration of PA at the lysosomal surface do not reach the
same concentration than exogenously added PA.
In conclusion, ICSN3250 deﬁnes a new class of mTORC1
inhibitors that, due to its particular mechanism of action, induces
cell death speciﬁcally in tumor cells but not in noncancer cells.
Additional researches will determine the applicability of this type
of compound for anticancer therapy.
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